
商务合作

动脉网APP
可切换为仅中文
Boehringer Ingelheim has joined forces with digital health firm Brainomix on a project to improve the care of people with fibrosing lung diseases in the US.The new project will focus on the real-world use of Brainomix's artificial intelligence-powered Brainomix 360 e-Lung software, which was recently approved by the FDA in May to assist in the diagnosis and assessment of patients with interstitial lung diseases (ILDs) from medical images.ILDs represent a broad category of over 200 lung diseases that can cause scarring to the lungs, including pulmonary fibrosis, which is the main focus of the Boehringer partnership and a highly debilitating, life-limiting condition.The two companies will collaborate on the use of e-Lung to accelerate the diagnosis and improve access to treatment for people living with pulmonary fibrosis from CT scans.
勃林格殷格翰(Boehringer Ingelheim)与数字健康公司Brainomix联手实施一个项目,以改善美国纤维化肺病患者的护理。该新项目将重点关注Brainomix人工智能驱动的Brainomix 360电子肺软件的实际应用,该软件最近于5月获得FDA批准,用于帮助从医学图像中诊断和评估间质性肺病(ILD)患者。。两家公司将合作使用电子肺来加速诊断,并改善CT扫描肺纤维化患者的治疗机会。
The software will be deployed at top US pulmonology centres as well as referring sites, in order to validate its benefits and see how it can be used to 'optimise pathways of care and improve outcomes' for patients.If left untreated, patients with pulmonary fibrosis can have a lifespan as short as five years from diagnosis.
该软件将部署在美国顶级肺病中心以及转诊网站,以验证其益处,并了解如何使用它来“优化护理途径并改善患者的预后”。如果不及时治疗,肺纤维化患者的寿命可能短至五年。
It can be hard to distinguish the disease from other respiratory conditions, however, and patients can wait up to two years for diagnosis.The key to the best survival for patients with fibrosing lung disease is the earliest initiation of treatment, but identifying patients eligible for treatment based on imaging can be challenging, even for experts, according to Brainomix and Boehringer.'There is an urgent need to improve the identification of people with fibrosing lung disease,' said Dr Michalis Papadakis, who is chief executive and co-founder of Brainomix, a spinout from the University of Oxford in the UK.
然而,很难将该疾病与其他呼吸系统疾病区分开,患者可以等待长达两年的诊断。根据Brainomix和Boehringer的说法,纤维化肺病患者获得最佳生存的关键是尽早开始治疗,但根据影像学确定符合治疗条件的患者可能具有挑战性,即使对于专家来说也是如此英国牛津大学(University of Oxford)派生出的Brainomix首席执行官兼联合创始人米查利斯·帕帕达基斯(MichalisPapadakis)博士说,迫切需要改进对纤维化肺病患者的识别。
'This will en.
“这将是恩。